eligibility_summary
Adults (≥18) with LBCL (DLBCL NOS, FL3B, HGBCL NOS, MYC/BCL2 double‑hit, tFL→DLBCL w/o prior indolent), relapsed/refractory after first‑line CD20+anthracycline, measurable disease (Lugano), no CNS lymphoma, ECOG 0–2, life expectancy ≥3 mo, treatment washout, contraception/consent. Exclude: recent other cancers, prior HSCT, Richter, >1 prior line, prior PI3K, hypersensitivity, active infection, >10 mg steroids/immunosuppression, major organ disease, uncontrolled effusions/proteinuria, active autoimmune, HIV, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, open-label trial in relapsed/refractory large B‑cell lymphoma tests linperlisib added to rituximab-based salvage chemo (R‑GemOx or R‑ICE/DHAP/GVM), with auto‑HSCT for eligible responders. Drugs and mechanisms: linperlisib—oral selective PI3Kδ inhibitor blocking B‑cell receptor (BCR) signaling to curb malignant B‑cell survival/proliferation and modulate immune cells, rituximab—anti‑CD20 monoclonal antibody depleting B cells via ADCC/CDC/apoptosis, gemcitabine and cytarabine—antimetabolite nucleoside analogs inhibiting DNA synthesis, oxaliplatin/cisplatin/carboplatin—platinum DNA cross‑linkers, ifosfamide—alkylating agent, etoposide and liposomal mitoxantrone—topoisomerase II inhibitors, vinorelbine—microtubule inhibitor, dexamethasone—glucocorticoid with lympholytic effects. Targets: CD20+ malignant B cells, BCR–PI3Kδ pathway, DNA replication/repair, microtubules, and apoptosis/cell‑cycle pathways.